Literature DB >> 23528211

NF1 gene silencing induces upregulation of vascular endothelial growth factor expression in both Schwann and non-Schwann cells.

Yasuhiro Kawachi1, Hiroshi Maruyama, Yosuke Ishitsuka, Yasuhiro Fujisawa, Junichi Furuta, Yasuhiro Nakamura, Eiko Ichikawa, Minao Furumura, Fujio Otsuka.   

Abstract

Neurofibromatosis type I (NF1) is associated with typical hypervascular tumors, including neurofibroma, glioma, malignant peripheral nerve sheath tumors (MPNST) and glomus tumors. Previously, we and other groups reported that neurofibromas showed high-level expression of vascular endothelial growth factor (VEGF), a potent angiogenic factor involved in neovascularization. However, the molecular mechanism underlying the upregulation of VEGF in neurofibromas remains unclear. In this study, we examined the effects of Nf1 gene silencing on VEGF expression in Schwann cell and non-Schwann cell line and the upstream mTOR-HIF-1α - VEGF pathway in Schwann cell line. The results indicated that Nf1 gene silencing by lentiviral-mediated RNA interference resulted in elevated expression of VEGF, HIF-1α and phosphorylated mTOR at the protein level. The results obtained from Nf1 gene silencing in murine Schwann cell line analogously suggest that NF1 gene haploinsufficiency in human tumor Schwann cells may directly elicit upregulation of VEGF expression without the tumor microenvironment by activation of the mTOR-HIF-1α - VEGF pathway. We also showed that interleukin-6 is upregulated in Nf1 gene knock-down Schwann cells at the protein level.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23528211     DOI: 10.1111/exd.12115

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  10 in total

Review 1.  The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.

Authors:  Souvik Karmakar; Karlyne M Reilly
Journal:  CNS Oncol       Date:  2016-12-21

2.  Epidermal expression of Lgr6 is dependent on nerve endings and Schwann cells.

Authors:  Xin-Hua Liao; Hoang Nguyen
Journal:  Exp Dermatol       Date:  2014-03       Impact factor: 3.960

3.  A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.

Authors:  Nicole J Ullrich; Sanjay P Prabhu; Alyssa T Reddy; Michael J Fisher; Roger Packer; Stewart Goldman; Nathan J Robison; David H Gutmann; David H Viskochil; Jeffrey C Allen; Bruce Korf; Alan Cantor; Gary Cutter; Coretta Thomas; John P Perentesis; Tomoyuki Mizuno; Alexander A Vinks; Peter E Manley; Susan N Chi; Mark W Kieran
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

4.  Segmental neurofibromatosis presenting with congenital excessive skin folds.

Authors:  Alexander M Helfand; Ariella Nouriel; Jonah Zisquit; Aviv Barzilai; Shoshana Greenberger
Journal:  Dermatol Pract Concept       Date:  2015-04-30

5.  Glomus tumor of the thenar eminence in neurofibromatosis type 1: case report and literature review.

Authors:  Gabriele Scaravilli; Roberto Rossi; Stefano Artiaco; Giovanni Merolla
Journal:  Transl Med UniSa       Date:  2014-12-19

6.  Bevacizumab for Treatment-Refractory Pain Control in Neurofibromatosis Patients.

Authors:  Xu W Linda; Lawrence D Recht
Journal:  Cureus       Date:  2016-12-18

7.  Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.

Authors:  Hanfang Zhang; Farlyn Z Hudson; Zhimin Xu; Rebekah Tritz; Modesto Rojas; Chintan Patel; Stephen B Haigh; Zsuzsanna Bordán; David A Ingram; David J Fulton; Neal L Weintraub; Ruth B Caldwell; Brian K Stansfield
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-05-01       Impact factor: 4.799

8.  RAS and beyond: the many faces of the neurofibromatosis type 1 protein.

Authors:  Corina Anastasaki; Paola Orozco; David H Gutmann
Journal:  Dis Model Mech       Date:  2022-02-21       Impact factor: 5.732

9.  Geometrical versus Random β-TCP Scaffolds: Exploring the Effects on Schwann Cell Growth and Behavior.

Authors:  Lauren Sweet; Yunqing Kang; Christopher Czisch; Lukasz Witek; Yang Shi; Jim Smay; Giles W Plant; Yunzhi Yang
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

Review 10.  Cutaneous neurofibromas in the genomics era: current understanding and open questions.

Authors:  Robert J Allaway; Sara J C Gosline; Salvatore La Rosa; Pamela Knight; Annette Bakker; Justin Guinney; Lu Q Le
Journal:  Br J Cancer       Date:  2018-04-26       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.